Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have signs and/or symptoms or documented diagnosis of Psoriatic Arthritis (PsA) for at least 6 months and currently fulfilling the classification of Psoriatic Arthritis (CASPAR) criteria.
Have active PsA, defined as the presence of at least 3 of 68 tender joints and at least 3 of 66 swollen joints.
Have obesity, body mass index of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) or overweight (BMI ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).
You may not be if
Medical Conditions
Have Type 1 Diabetes Mellitus (T1DM).
Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
Have a prior or planned surgical treatment for obesity.
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
Have active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).
Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:
* basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years.
* cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.
Have a serious disorder or illness other than PsA.
Have a history of chronic or acute pancreatitis.
Have any prior use of ixekizumab or tirzepatide.
Diagnosis of other inflammatory arthritis, such as Rheumatoid Arthritis (RA), ankylosing spondylitis, reactive arthritis, gout, or enteropathic arthritis.
Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.
